Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structural development of biological response modifiers based on thalidomide.

Yuichi Hashimoto1

  • 1Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan. hashimot@iam.u-tokyo.ac.jp

Bioorganic & Medicinal Chemistry
|January 30, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phthalimide: a potential warhead for switchable and bioorthogonal conjugation.

Chemical communications (Cambridge, England)·2025
Same author

Photo-Enhanced Aqueous Solubilization of Azobenzene-Incorporated Lipids.

Chemical & pharmaceutical bulletin·2025
Same author

Development of subtype-selective estrogen receptor modulators using the bis(4-hydroxyphenyl)silanol core as a stable isostere of bis(4-hydroxyphenyl)methanol.

RSC advances·2023
Same author

Distribution of Retinoids Applied Exogenously to Chick Limb Buds: an Autoradiographic Analysis: (Retinoic Acid/Limb Bud/Pattern Formation/Autoradiograph).

Development, growth & differentiation·2023
Same author

Design, synthesis and structure-activity relationship of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxyisoprop-2-yl)phenylsilane derivatives as liver X receptor agonists.

Bioorganic & medicinal chemistry·2022
Same author

Conversion of a PROTAC Mutant Huntingtin Degrader into Small-Molecule Hydrophobic Tags Focusing on Drug-like Properties.

ACS medicinal chemistry letters·2022
Same journal

Recent advances in Camptothecin-derived antibody-drug conjugates.

Bioorganic & medicinal chemistry·2026
Same journal

CDK4/6-targeted therapy: From clinical inhibitors to emerging strategies to overcome resistance.

Bioorganic & medicinal chemistry·2026
Same journal

Coumarin-sulfonamide hybrids as PKM2 activators induce metabolic reprogramming and suppress ovarian cancer cell growth.

Bioorganic & medicinal chemistry·2026
Same journal

Recent advances in the development of small-molecule drugs based on covalent reversible inhibitors.

Bioorganic & medicinal chemistry·2026
Same journal

Computational hybrid approach of PBPK simulation and CGCNN models for human intravenous pharmacokinetics.

Bioorganic & medicinal chemistry·2026
Same journal

Assessing the use of foundation model embeddings to improve drug response predictions using scRNA-Seq expression data.

Bioorganic & medicinal chemistry·2026
See all related articles

Thalidomide, once withdrawn for teratogenicity, shows renewed promise for treating cancers and AIDS. Its diverse pharmacological effects stem from multiple molecular targets, driving structural development studies.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Drug Development

Background:

  • Thalidomide, a hypnotic/sedative, was withdrawn due to severe teratogenicity.
  • Recent interest stems from its potential in treating acquired immunodeficiency syndrome (AIDS) and cancers.
  • Thalidomide exhibits pleiotropic effects, acting as a multi-target drug.

Purpose of the Study:

  • To review structural development studies of thalidomide.
  • To correlate these studies with the drug's known pharmacological effects.
  • To explore thalidomide's multi-target activities.

Main Methods:

  • Focus on structural development studies.
  • Investigate tumor necrosis factor-alpha (TNF-alpha) production-regulating activity.
  • Examine anti-androgenic, puromycin-sensitive aminopeptidase-inhibiting, and alpha-glucosidase-inhibiting activities.

Related Experiment Videos

Main Results:

  • Thalidomide's structural modifications are linked to its diverse biological activities.
  • Studies highlight its multi-target nature, influencing various enzymes and pathways.
  • Development efforts focus on harnessing specific activities while mitigating side effects.

Conclusions:

  • Thalidomide's resurgence is due to its versatile pharmacological profile.
  • Structural studies are crucial for understanding and optimizing its therapeutic potential.
  • The drug's multi-target action offers avenues for novel therapeutic strategies in oncology and infectious diseases.